Onward Med Nv

Good day and thank you for standing by. Welcome to the Onward Medical first half 2026 results webcast. At this time all participants are in a listen only mode. After the speaker's presentation there will be a question and answer session. To ask a question during the session you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question please press star 1 and 1 again. Alternatively, you may submit your question via the webcast. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sebastien Cros, Head of Communications. Please go ahead.

Thank you, Mel. Good morning, good afternoon, everyone, and welcome to ONWARD's webcast following our results for the first half of 2026. Before we get started, Please take a moment to read the usual disclaimer. This deck includes forward-looking statements which should be considered with the appropriate level of caution as outlined on this page. The deck and a recording of the webcast will be available on our investor platform after the call. Today for the call, I'm joined with four members of Onward's leadership team, Dave, our CEO, Ali, CFO, our Chief Clinical Regulatory and Quality Officer, and Sean, our Chief Commercial Officer. We'll start by covering the results and key highlights from the first half of the year before opening the floor for questions. You may submit your questions orally or via the Q&A module on the platform. With that, I'll hand over to Dave.

Thank you, Seb. I have an easy job today because I've got my leadership team carrying most of the weight. Thank you everyone for joining. Let me start with the highlights. Very strong quarter again. 159 RTX systems were sold or supplied via paid evaluation in the first half of 2026. That's More than a 5x increase year over year. ARC-EX systems were available in over 130 US clinics and 150 clinics worldwide in the first half. We also achieved implants in the ARC-IM Pivotal Trial called Empower BP to address blood pressure instability after spinal cord injury. 22 participants are enrolled in the study and 14 clinical sites are now active to date. So that's all the sites in the US and Canada and Europe is next. We initiated the Iger feasibility study for Arc IM mobility. This is an important study. It's a precursor to an eventual pivotal study for this indication. We successfully implanted an additional patient in the Parkinson's disease blood pressure trial, something called PD-Hemon. and we announced two additional ARC BCI implants extending our global leadership in this realm. We reported 4.2 million euros in revenue, that's a 250% year-over-year increase and we ended the first half with a cash balance of 81.5 million euros. We raised over 40 million in new equity capital including a 25 million euro investment from EQT Life Sciences and we replaced our existing loan with an up to 50 million euro debt facility from BlackRock. With that, I'd like to turn it over to Sean, our Chief Commercial Officer.